deaths (OS)progression or deaths (PFS)RFS/DFS

la/mBC - HER2 positive - 1st Line (L1) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 1st Line (L1)

versus trastuzumab
pertuzumab plus trastuzumab vs. trastuzumab 1 0.65
versus trastuzumab plus chemotherapy
trastuzumab plus endocrine therapy vs. trastuzumab plus chemotherapy 1 0.820.88
versus trastuzumab plus docetaxel
pertuzumab plus trastuzumab plus docetaxel vs. trastuzumab plus docetaxel 2 0.660.64

la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)

versus lapatinib plus capecitabine
neratinib plus capecitabine vs. lapatinib plus capecitabine 2 0.880.74
versus placebo
neratinib vs. placebo 1
versus trastuzumab plus capecitabine
tucatinib plus trastuzumab plus capecitabine vs. trastuzumab plus capecitabine 2 0.660.54